TY - JOUR
T1 - Improving lung health in low-income and middle-income countries
T2 - from challenges to solutions
AU - Meghji, Jamilah
AU - Mortimer, Kevin
AU - Agusti, Alvar
AU - Allwood, Brian W.
AU - Asher, Innes
AU - Bateman, Eric D.
AU - Bissell, Karen
AU - Bolton, Charlotte E.
AU - Bush, Andrew
AU - Celli, Bartolome
AU - Chiang, Chen Yuan
AU - Cruz, Alvaro A.
AU - Dinh-Xuan, Anh Tuan
AU - El Sony, Asma
AU - Fong, Kwun M.
AU - Fujiwara, Paula I.
AU - Gaga, Mina
AU - Garcia-Marcos, Luis
AU - Halpin, David M.G.
AU - Hurst, John R.
AU - Jayasooriya, Shamanthi
AU - Kumar, Ajay
AU - Lopez-Varela, Maria V.
AU - Masekela, Refiloe
AU - Mbatchou Ngahane, Bertrand H.
AU - Montes de Oca, Maria
AU - Pearce, Neil
AU - Reddel, Helen K.
AU - Salvi, Sundeep
AU - Singh, Sally J.
AU - Varghese, Cherian
AU - Vogelmeier, Claus F.
AU - Walker, Paul
AU - Zar, Heather J.
AU - Marks, Guy B.
N1 - Funding Information:
We acknowledge the support of the following organisations and their members who have contributed to this Review: the Global Initiative for Asthma, the Global Initiative for COPD, the Global Asthma Network, The Union, the Pan African Thoracic Society, the British Thoracic Society Global Health Group, the European Respiratory Society, the Asian Pacific Society of Respirology, the Asociacion Latinoamericana de Torax, and the World Health Organization. We thank the National Institute for Health Research (NIHR) Global Health Research Unit on Lung Health and TB in Africa at the Liverpool School of Tropical Medicine (IMPALA) (16/136/35) for facilitating this collaboration. IMPALA was funded by the NIHR using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, the UK Department of Health and Social Care, or other affiliated organisations.
Funding Information:
AA is the current Chair of the Board of Directors of GOLD. EDB is a member of the Science Committee and Board of GINA. He reports personal fees from AstraZeneca, ALK, Boehringer Ingelheim, Menarini, Novartis, Orion, Regeneron, and Sanofi Genzyme. BWA reports honoraria received from Novartis. CEB reports grants from the Global Challenges Research Fund and the University of Nottingham (Nottingham, UK). BC reports personal fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Sanofi Aventis, and Menarini. AAC reports grants and personal fees from GSK, and personal fees from Sanofi, Boehringer Ingelheim, AstraZeneca, Novartis, Chiesi, Eurofarma, Mylan, and Mantecorp. KMF reports non-financial support from NanoString technologies, Olympus, and MeVis Veolity for research activities, and grant funding from the International Association for the Study of Lung Cancer (IASLC) and the NIH. MG reports grants and personal fees from Novartis and Menarini, grants from Galapagos, Elpen, and AstraZeneca, and personal fees from BMS and MSD. JRH reports personal fees and non-financial support from pharmaceutical companies. GBM reports grants and other support from AstraZeneca, and grants from GSK Australia. HKR is Chair of the GINA Science Committee and reports grants and personal fees from AstraZeneca and GlaxoSmithKline, and personal fees from Merck, Novartis, Teva, Boehringer Ingelheim, and Sanofi Genzyme. CFV reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, and Novartis; personal fees from Berlin Chemie/Menarini, CSL Behring, Nuvaira and MedUpdate; and grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET). KM reports personal fees from AstraZeneca. All other authors declare no competing interests.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/3/6
Y1 - 2021/3/6
N2 - Low-income and middle-income countries (LMICs) bear a disproportionately high burden of the global morbidity and mortality caused by chronic respiratory diseases (CRDs), including asthma, chronic obstructive pulmonary disease, bronchiectasis, and post-tuberculosis lung disease. CRDs are strongly associated with poverty, infectious diseases, and other non-communicable diseases (NCDs), and contribute to complex multi-morbidity, with major consequences for the lives and livelihoods of those affected. The relevance of CRDs to health and socioeconomic wellbeing is expected to increase in the decades ahead, as life expectancies rise and the competing risks of early childhood mortality and infectious diseases plateau. As such, the World Health Organization has identified the prevention and control of NCDs as an urgent development issue and essential to the achievement of the Sustainable Development Goals by 2030. In this Review, we focus on CRDs in LMICs. We discuss the early life origins of CRDs; challenges in their prevention, diagnosis, and management in LMICs; and pathways to solutions to achieve true universal health coverage.
AB - Low-income and middle-income countries (LMICs) bear a disproportionately high burden of the global morbidity and mortality caused by chronic respiratory diseases (CRDs), including asthma, chronic obstructive pulmonary disease, bronchiectasis, and post-tuberculosis lung disease. CRDs are strongly associated with poverty, infectious diseases, and other non-communicable diseases (NCDs), and contribute to complex multi-morbidity, with major consequences for the lives and livelihoods of those affected. The relevance of CRDs to health and socioeconomic wellbeing is expected to increase in the decades ahead, as life expectancies rise and the competing risks of early childhood mortality and infectious diseases plateau. As such, the World Health Organization has identified the prevention and control of NCDs as an urgent development issue and essential to the achievement of the Sustainable Development Goals by 2030. In this Review, we focus on CRDs in LMICs. We discuss the early life origins of CRDs; challenges in their prevention, diagnosis, and management in LMICs; and pathways to solutions to achieve true universal health coverage.
UR - http://www.scopus.com/inward/record.url?scp=85101909339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101909339&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)00458-X
DO - 10.1016/S0140-6736(21)00458-X
M3 - Review article
C2 - 33631128
AN - SCOPUS:85101909339
SN - 0140-6736
VL - 397
SP - 928
EP - 940
JO - The Lancet
JF - The Lancet
IS - 10277
ER -
